Precancerous Condition clinical trials at UC Cancer

• A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

  open to eligible people ages 18 years and up

  Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

  at UCLA

Last updated: August 23, 2021